|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0027651,
umls-concept:C0035647,
umls-concept:C0069515,
umls-concept:C0205179,
umls-concept:C0205210,
umls-concept:C0242957,
umls-concept:C0376525,
umls-concept:C0439849,
umls-concept:C0441655,
umls-concept:C0449438,
umls-concept:C0681890,
umls-concept:C1140680,
umls-concept:C1328025,
umls-concept:C1879547,
umls-concept:C1999216
|
|
pubmed:issue |
26
|
|
pubmed:dateCreated |
2006-9-11
|
|
pubmed:abstractText |
Ovarian cancers (OCs) frequently have HER2 activation in the absence of HER2 overexpression. Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/pertuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AghajanianCarolC,
pubmed-author:AllisonDavid EDE,
pubmed-author:BrewerMollyM,
pubmed-author:CohnDavid EDE,
pubmed-author:DereRandall CRC,
pubmed-author:DerynckMika KMK,
pubmed-author:EberhardDavid ADA,
pubmed-author:FlemingGini FGF,
pubmed-author:GarciaAgustin AAA,
pubmed-author:GordonMichael SMS,
pubmed-author:HainsworthJohn DJD,
pubmed-author:KarlanBeth YBY,
pubmed-author:LyonsBenjaminB,
pubmed-author:MateiDanielaD,
pubmed-author:MatulonisUrsula AUA,
pubmed-author:NgKimmieK,
pubmed-author:PegramMark DMD,
pubmed-author:PhamThinh QTQ,
pubmed-author:RomanLyndaL,
pubmed-author:SchilderRussell JRJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4324-32
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16896006-Adult,
pubmed-meshheading:16896006-Aged,
pubmed-meshheading:16896006-Aged, 80 and over,
pubmed-meshheading:16896006-Antibodies, Monoclonal,
pubmed-meshheading:16896006-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16896006-Antineoplastic Agents,
pubmed-meshheading:16896006-Dimerization,
pubmed-meshheading:16896006-Disease-Free Survival,
pubmed-meshheading:16896006-Drug Administration Schedule,
pubmed-meshheading:16896006-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:16896006-Female,
pubmed-meshheading:16896006-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16896006-Genes, erbB-2,
pubmed-meshheading:16896006-Humans,
pubmed-meshheading:16896006-Middle Aged,
pubmed-meshheading:16896006-Neoplasm Staging,
pubmed-meshheading:16896006-Ovarian Neoplasms,
pubmed-meshheading:16896006-Predictive Value of Tests,
pubmed-meshheading:16896006-Receptor, erbB-2,
pubmed-meshheading:16896006-Tumor Markers, Biological
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
|
|
pubmed:affiliation |
Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
